Innocan Pharma Announces First Quarter 2025 Financial Results with Continued Strong Revenue Growth and Provides Corporate Update
HERZLIYA, Israel and CALGARY, AB, May 28, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the " Company" or " Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its financial consolidated results for the first quarter ended March 31, 2025, and provides a corporate update on its recent activities and upcoming milestones.
Key Business Highlights
US $1 million raised through Private Placement - on March 7, 2025, the Company completed a non-brokered private placement of a debenture unit (the " Debenture Unit") to its largest shareholder, Tamar Innovest Ltd., raising US $1 million.
First Quarter 2025 Financial Highlights
Revenues increased 15% in the first quarter of 2025 to US$7.8 million, compared to US$6.8 million in the first quarter of 2024. This increase in revenue was due to the robust sales performance of Innocan's subsidiary, BI Sky Global Ltd.
Gross Profit increased 19% in the first quarter of 2025 to US$7.1 million, compared to US$6.0 million in the first quarter of 2024.
Operating loss decreased by 140% to operating profit of US$0.5 million in the first quarter of 2025, compared to operating loss of US$1.2 million in the first quarter of 2024.
Corporate Highlights and Business Update
Broaden Intellectual Property Coverage for Liposomal CBD Injection Across Asia.
The Company reported advancing its efforts to strengthen the protection of its intellectual property across additional Asian markets, following the recently granted patent in India for a prolonged-release pharmaceutical formulation using liposomes to encapsulate CBD. The liposomal drug delivery platform allows for prolonged exposure and maximizes the bioavailability and therapeutic effects of CBD.
Innocan's synthetic CBD-loaded Liposome Injection Platform (LPT-CBD) received positive feedback from the U.S. Food and Drug Administration (FDA) following a successful pre-IND meeting to advance its development as a non-opioid alternative for chronic pain management. The Indian patent, granted in a pharmaceutical market estimated at US $55 billion (Bain & Company) complements Innocan's global patent applications, strengthening the proprietary value of its novel liposome-based cannabinoid technology.
In addition, Innocan reported the filing of this divisional application for its LPT-CBD technology in China which management believes reflects the expertise and commitment of Innocan's team and represents a strategic step in aligning the Company's intellectual property portfolio with its long-term global business objectives. This application aims to protect LPT-CBD.
The FDA's Center for Veterinary Medicine (CVM) has granted Innocan a sponsor fee waiver for its LPT-CBD product for the second consecutive year. Following a thorough review, the CVM granted Innocan the 2025 fee waiver, recognizing the Company's continued pursuit of innovative animal drug products and technology. The waiver applies to the Company's LPT-CBD drug product, developed for subcutaneous injection to manage chronic pain in dogs. With growing interest in CBD products among pet owners seeking safe and effective ways to support their pets' health, Innocan's LPT-CBD aims to deliver precise and sustained CBD release from a single injection. This innovation offers a safe and convenient dosing solution for managing chronic pain in dogs, providing benefits for pets of all ages and sizes.
Management Comments
Iris Bincovich, CEO of Innocan Pharma, commented: "We are very pleased with our strong start to 2025, marked by solid results in the first quarter. This positive momentum reflects the dedication and excellence of our team. We continued to deliver meaningful, customer-centric innovation while maintaining a disciplined approach to operational management. Our progress this quarter reinforces our confidence in our strategic direction and positions us well for continued success throughout the year."
"We are moving forward with the FDA approval process for our LPT-CBD delivery system designed for precise dosing and sustained release into the bloodstream, targeting chronic pain relief. Our commitment to innovation and improving patient outcomes remains at the core of everything we do. It's an exciting time for Innocan and our shareholders."
Roni Kamhi, CEO of BI Sky Global and COO of Innocan Pharma, commented: "We're very encouraged by the performance of the results in Q1 2025. We are continuing to move forward in both segments "LPT platform - and our consumer wellness. At BI Sky Global, our products continue to gain the trust of millions of customers. We are leveraging our deep expertise in the cosmetics industry along with advanced data analytics to better understand and meet the evolving needs of our customers. Looking ahead, we're focused on further strengthening BI Sky Global's position as a leading company in the beauty and personal care market.
The Company's full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2025, and accompanying management's discussion and analysis can be accessed by visiting the Company's website at www.innocanpharma.com and its SEDAR+ profile at www.sedarplus.ca.
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves its primary drug delivery technology, LPT-CBD loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: pain management and epilepsy. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan is a 40% shareholder in the joint venture company, BI Sky Global Ltd., which company focuses on advanced targeted online sales. https://innocanpharma.com/
For further information, please contact:
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Cautionary note regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Edmonton Journal
16 hours ago
- Edmonton Journal
Jets sign defenceman Alfons Freij to three-year, entry-level contract
Article content The Winnipeg Jets have signed defenceman Alfons Freij to a three-year, entry-level contract, the team announced Saturday. The average annual value of the deal in the NHL is $975,000 US. Article content Friej, 19, played 29 games for Bjorkloven IF in the Swedish HockeyAllsvenskan and had eight points (two goals, six assists) and 12 penalty minutes. The six-foot-one, 192-pound blueliner also played five games for the Bjorkloven IF junior team in the J20 Nationell and had five points (two goals, three assists) and two PIMs. He added a pair of assists and four PIMs in two playoff games. Freij was Winnipeg's second-round pick (37th overall) in the 2024 NHL Draft. Article content Article content Latest National Stories
Montreal Gazette
19 hours ago
- Montreal Gazette
Opinion: U.S. vaccine funding cancellation is disastrous
With Donald Trump's second administration, disruptive news seems to arise on a daily basis. Most concerning for clinicians and health scientists in Canada and around the world was Trump's appointment of anti-vaccination advocate Robert F. Kennedy Jr. to the enormously influential position of secretary of health and human services. Kennedy's ideological dismantling of the U.S.'s vaunted health research apparatus has been at a speed that's surprising even to his most ardent critics. But his recent decision to cancel a nearly US$600-million contract with vaccine manufacturer Moderna may be among his most short-sighted and destructive moves, with ripple effects globally. The contract with the mRNA pioneer, signed under the Joe Biden administration, was meant to fund the development, testing and licensing of vaccines targeting particular flu strains, including the strain responsible for the dreaded avian flu, H5N1. Many scientists fear H5N1 could become the next world-stopping infectious disease pandemic. The main reason cited for the cancellation was concern for the safety and testing of mRNA vaccine technology. But the company's mRNA COVID vaccines are among the most tested and scrutinized medical products in human history. The withdrawal of the U.S. from efforts to produce an mRNA vaccine against H5N1 is indeed troubling. When it infects humans, H5N1 kills about 50 per cent of the time. Canada's only known domestically acquired human case of H5N1 to date was discovered in November. The current outbreak among dairy herds in the U.S. has spread to at least 17 states and more than 1,000 herds. The increasing number of domestic and wild animals found to be infected is worrying, suggesting that the dreaded mutation allowing easy human-to-human transmission is becoming more likely by the day. When that happens, many people will die, and many more will clamour for a vaccine. Luckily, we already have more than one licensed H5N1 vaccine based on older, non-mRNA technology. But their efficacy is largely unknown, and many of them are manufactured via incubating the virus inside live eggs. In the event of an avian flu pandemic, finding enough uninfected eggs to produce doses at scale could be problematic. More challenging is the lead time for manufacturing these traditional vaccines. At the very least, many months are needed, which is why the seasonal flu vaccine is often a poor match to circulating strains, resulting in middling efficacy. If an H5N1 pandemic is in our near future, it will not be possible to manufacture sufficient doses of the currently licensed vaccines quickly enough to protect everyone. The only proven vaccine technology capable of the kind of rapid production needed to quell a sudden pandemic is the mRNA platform. Five years of refinement over the course of the COVID era has afforded Moderna and Pfizer a kind of confident fluency in their development and deployment acumen. Other companies have since adopted the technology as well. Another consideration is viral mutation. If H5N1 makes the mutational leap to sustained human-to-human transmission, it will be because its genetic makeup will have changed enough to make that happen. In other words, the virus will be measurably different from that used to create the currently licensed formulations. The mRNA platform will be needed to quickly pivot to targeting the new viral formulation. It can do so with much more adeptness and fluidity than the lumbering egg- and cell-incubated vaccines currently stockpiled. Remember: the first COVID mRNA vaccine was finalized just 48 hours after scientists sequenced the genetic code of the virus that causes COVID. RFK Jr.'s decision to cancel this funding is short-sighted and seemingly driven by skewed and nonsensical anti-vax perceptions. It comes at a time when early clinical trials had already demonstrated the safety of Moderna's investigational pandemic influenza vaccine, called mRNA-1018. Perhaps this is an opportunity for other countries — such as Canada — to fill the funding void and claim the financial and societal benefits of this transformational technology.
Winnipeg Free Press
a day ago
- Winnipeg Free Press
‘Gas station heroin' is technically illegal and widely available. Here are the facts
WASHINGTON (AP) — Health officials want you to think twice before buying one of those brightly colored little bottles often sold at gas stations, convenience stores and smoke shops. Sometimes called 'gas station heroin,' the products are usually marketed as energy shots or cognitive supplements but actually contain tianeptine, an unapproved drug that can be addictive and carries risks of serious side effects. U.S. poison control centers have reported a steady rise in calls linked to the drug for more than a decade. And last month the Food and Drug Administration sent a warning to health professionals about 'the magnitude of the underlying danger or these products.' Here's what to know about gas station heroin. How are these products sold in the U.S.? Tianeptine is approved in a number foreign countries as an antidepressant, usually as a low-dose pill taken three times a day. But it has never been approved by the FDA for any medical condition in the U.S. Additionally, the drug cannot legally be added to foods and beverages or sold as a dietary supplement — something the FDA has repeatedly warned U.S. companies about. Still, under-the-radar firms sell tianeptine in various formulas, often with brand names like Zaza, Tianaa, Pegasus and TD Red. Although that is technically illegal, the FDA does not preapprove ingredients added to supplements and beverages. 'It's kind of this grey area of consumer products, or supplements, where the contents are not regulated or tested the way they would be with a medication,' said Dr. Diane Calello of the New Jersey Poison Information and Education System. Last year, Calello and her colleagues published a study documenting a cluster of emergency calls in New Jersey tied to a flavored elixir called Neptune's Fix. People experienced distress, rapid heartbeat, low blood pressure and seizures after drinking it. More than a dozen of the 20 patients had to be admitted for intensive care. Why use these products? Many tianeptine products claim— without evidence or FDA approval— to help users treat medical conditions, including addiction, pain and depression. In 2018, the FDA issued a warning letter to the maker of a product called Tianna, which claimed to provide 'an unparalleled solution to cravings for opiates.' While tianeptine is not an opioid, the drug binds to some of the same receptors in the brain, which can temporarily produce effects akin to oxycodone and other opioids. Tianeptine also carries some of the same physiological risks of opioids, including the potential to dangerously depress breathing. 'That's what tends to get people into trouble,' said Dr. Hannah Hays of Nationwide Children's Hospital in Columbus, Ohio. 'They use it for opioid-like effects or to self-treat opioid withdrawal and that can lead to slow breathing and problems like that.' People dealing with opioid addiction, pain, depression, anxiety and other conditions should see a health professional to get a prescription for FDA-approved treatments, Hays said. Is tianeptine use going up? Experts aren't sure but national figures show a big rise in emergency calls involving the drug. Calls to poison control centers increased 525% between 2018 and 2023, according to a data analysis published earlier this year. In about 40% of cases, the person had to seek medical care, with more than half of them needing critical care. One explanation for the rise in calls is simply that more Americans are using the products. But experts also say that the products are triggering more emergencies as they become more potent and dangerous. And the researchers in New Jersey who analyzed Neptune's Fix found that the liquid also contained synthetic cannabis and other drugs. 'You never quite know what's in that bottle,' Calello said. 'It's important for people to know that even if they have used a product before, they could get a bottle that contains something very different from what they're looking for.' Are there policies that could reduce tianeptine use? Tianeptine is not included in the federal Controlled Substances Act, which bans or restricts drugs that have no medical use or have a high potential for abuse, such as heroin, LSD and PCP. But about a dozen states have passed laws prohibiting or restricting tianeptine, including Alabama, Georgia, Michigan, Minnesota, Ohio and Tennessee. In some cases, those laws have led to more cases of withdrawal among users of tianeptine, which can be chemically addictive. But state data also shows some success in reducing harm tied to the drug. Until recently, Alabama had the highest rate of tianeptine-related calls in the southern U.S., which increased more than 1,400% between 2018 to 2021. But after the state restricted tianeptine in 2021 calls began modestly decreasing while calls across other southern states continued to climb. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
